Compare Stocks: IRD, ABSI, IMCR, and INBX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.74	$8.78	$2.24 ▼ $12.06	$1.67B	2.42	3.73 million shs	3.19 million shs
IMCR Immunocore	$30.72	$34.44	$27.56 ▼ $40.71	$1.58B	0.74	357,824 shs	271,995 shs
INBX Inhibrx Biosciences	$99.61	$101.24	$28.16 ▼ $155.29	$1.47B	3.66	349,952 shs	158,652 shs
IRD Opus Genetics	$4.76	$4.19	$1.50 ▼ $7.07	$393.41M	0.58	5.21 million shs	1.24 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	+0.93%	+11.83%	-14.19%	+256.78%
IMCR Immunocore	0.00%	-4.00%	-16.11%	+0.99%	-9.70%
INBX Inhibrx Biosciences	0.00%	-8.91%	-19.29%	+4.30%	+204.80%
IRD Opus Genetics	0.00%	-8.11%	+29.00%	+17.24%	+161.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$9.74	$8.78	$2.24 ▼ $12.06	$1.67B	2.42	3.73 million shs	3.19 million shs
IMCR Immunocore	$30.72	$34.44	$27.56 ▼ $40.71	$1.58B	0.74	357,824 shs	271,995 shs
INBX Inhibrx Biosciences	$99.61	$101.24	$28.16 ▼ $155.29	$1.47B	3.66	349,952 shs	158,652 shs
IRD Opus Genetics	$4.76	$4.19	$1.50 ▼ $7.07	$393.41M	0.58	5.21 million shs	1.24 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	0.00%	+0.93%	+11.83%	-14.19%	+256.78%
IMCR Immunocore	0.00%	-4.00%	-16.11%	+0.99%	-9.70%
INBX Inhibrx Biosciences	0.00%	-8.91%	-19.29%	+4.30%	+204.80%
IRD Opus Genetics	0.00%	-8.11%	+29.00%	+17.24%	+161.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.80	Moderate Buy	$13.71	40.80% Upside
IMCR Immunocore	2.58	Moderate Buy	$56.38	83.51% Upside
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	98.27% Upside
IRD Opus Genetics	2.89	Moderate Buy	$11.92	150.48% Upside

Current Analyst Ratings Breakdown

Latest IRD, ABSI, IMCR, and INBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	ABSI Absci	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/23/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/18/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
9/11/2026	INBX Inhibrx Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/10/2026	IRD Opus Genetics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $13.00
9/9/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$13.00 ➝ $16.00
9/9/2026	ABSI Absci	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/9/2026	IRD Opus Genetics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$10.00 ➝ $20.00
9/9/2026	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/9/2026	IRD Opus Genetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$12.00
9/9/2026	IRD Opus Genetics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$13.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	596.96	N/A	N/A	$1.26 per share	7.73
IMCR Immunocore	$400.02M	3.96	N/A	N/A	$7.52 per share	4.09
INBX Inhibrx Biosciences	$1.30M	1,127.89	N/A	N/A	$0.55 per share	181.11
IRD Opus Genetics	$14.20M	27.71	N/A	N/A	$0.22 per share	21.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.80	N/A	N/A	N/A	-7,756.38%	-61.71%	-54.52%	11/16/2026 (Estimated)
IMCR Immunocore	-$35.51M	-$0.37	N/A	122.88	N/A	-4.20%	-4.54%	-1.66%	11/5/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
IRD Opus Genetics	-$49.59M	-$1.35	N/A	N/A	N/A	-1,091.82%	-338.88%	-150.13%	11/11/2026 (Estimated)

Latest IRD, ABSI, IMCR, and INBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/11/2026	Q2 2026	ABSI Absci	-$0.1910	-$0.21	-$0.0190	-$0.21	$0.92 million	$0.32 million
8/7/2026	Q2 2026	IMCR Immunocore	-$0.01	-$0.02	-$0.01	-$0.02	$148.57 million	N/A
8/6/2026	Q2 2026	IRD Opus Genetics	-$0.1567	-$0.14	+$0.0167	-$0.14	$2.63 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	10.63	10.63
IMCR Immunocore	0.94	4.47	4.44
INBX Inhibrx Biosciences	12.58	5.07	5.07
IRD Opus Genetics	N/A	12.19	12.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
IMCR Immunocore	84.50%
INBX Inhibrx Biosciences	82.46%
IRD Opus Genetics	14.97%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
IMCR Immunocore	10.10%
INBX Inhibrx Biosciences	18.26%
IRD Opus Genetics	11.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	140	171.61 million	153.56 million	Optionable
IMCR Immunocore	524	51.50 million	46.30 million	Optionable
INBX Inhibrx Biosciences	110	14.72 million	12.03 million	Optionable
IRD Opus Genetics	28	82.65 million	72.98 million	N/A

IRD, ABSI, IMCR, and INBX Headlines

Recent News About These Companies

Head-To-Head Review: ProQR Therapeutics (NASDAQ:PRQR) versus Opus Genetics (NASDAQ:IRD)

September 26 at 4:58 AM | americanbankingnews.com

Wall Street Zen Downgrades Opus Genetics (NASDAQ:IRD) to Sell

September 26 at 1:25 AM | americanbankingnews.com

Opus Genetics (NASDAQ:IRD) Downgraded by Wall Street Zen to "Sell"

September 26 at 1:23 AM | marketbeat.com

Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD

September 17, 2026 | marketbeat.com

Opus Genetics (IRD) Reports Five Early BIRD-1 Responses. Is Phase 3 Planning Justified?

September 16, 2026 | insidermonkey.com

Opus Genetics consensus price target increased 21.47% to $12.98

September 16, 2026 | msn.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pyxis Oncology (PYXS) and Opus Genetics (IRD)

September 10, 2026 | theglobeandmail.com

Opus Genetics (NASDAQ:IRD) Sees Large Volume Increase After Analyst Upgrade

September 10, 2026 | marketbeat.com

Opus Genetics (NASDAQ:IRD) Given New $13.00 Price Target at Wedbush

September 10, 2026 | marketbeat.com

Wedbush Raises Price Target on Opus Genetics to $13 From $10, Keeps Outperform Rating

September 10, 2026 | marketscreener.comM

Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating

September 9, 2026 | marketscreener.comM

Clinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More

September 9, 2026 | rttnews.com

IRD stock hits over 5-year highs – Opus Genetics experimental therapy shows early promise in retinal diseases trial

September 9, 2026 | msn.com

Oppenheimer Issues Positive Forecast for Opus Genetics (NASDAQ:IRD) Stock Price

September 9, 2026 | marketbeat.com

Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial - Slideshow

September 9, 2026 | seekingalpha.com

HC Wainwright Reiterates Buy Rating for Opus Genetics (NASDAQ:IRD)

September 9, 2026 | marketbeat.com

Opus Genetics Reports Positive OPGx-BEST1 Data; Plans Potential Phase 3 Trial In 2027

September 9, 2026 | rttnews.com

Opus Genetics Reports Vision Improvement in Phase 1/2 OPGx-BEST1 Trial

September 9, 2026 | finance.yahoo.com

Opus Genetics reports positive OPGx-BEST1 phase 1/2 data, targets potential phase 3 dosing in 2027

September 9, 2026 | msn.com

Opus Genetics (NASDAQ:IRD) Given "Buy" Rating at BTIG Research

September 9, 2026 | marketbeat.com

Opus Genetics (NASDAQ:IRD) Hits New 12-Month High - Here's What Happened

September 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IRD, ABSI, IMCR, and INBX Company Descriptions

Absci NASDAQ:ABSI

$9.74 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$9.73 -0.01 (-0.14%)

As of 09/25/2026 07:59 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Immunocore NASDAQ:IMCR

$30.72 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$30.70 -0.02 (-0.07%)

As of 09/25/2026 07:30 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Inhibrx Biosciences NASDAQ:INBX

$99.61 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$99.66 +0.05 (+0.05%)

As of 09/25/2026 07:49 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Opus Genetics NASDAQ:IRD

$4.76 0.00 (0.00%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$4.73 -0.03 (-0.63%)

As of 09/25/2026 07:30 PM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, ABSI, IMCR, and INBX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, ABSI, IMCR, and INBX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, ABSI, IMCR, and INBX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, ABSI, IMCR, and INBX Company Descriptions

Absci NASDAQ:ABSI

Immunocore NASDAQ:IMCR

Inhibrx Biosciences NASDAQ:INBX

Opus Genetics NASDAQ:IRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IRD, ABSI, IMCR, and INBX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IRD, ABSI, IMCR, and INBX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IRD, ABSI, IMCR, and INBX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IRD, ABSI, IMCR, and INBX Company Descriptions

Absci NASDAQ:ABSI

Immunocore NASDAQ:IMCR

Inhibrx Biosciences NASDAQ:INBX

Opus Genetics NASDAQ:IRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools